Athan Pharmaceuticals products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Pharmaceutical and veterinary manufacturer · Hattar · Pakistan
Hattar-based pharmaceutical manufacturer active in human and veterinary medicines, with manufacturing and R&D operations.
Athan Pharmaceuticals products in Pakistan
Athan Pharmaceuticals has 2 medicine presentations registered in Pakistan under 1 brand, covering 1 generic medicine. Most of its products are in Anti-infectives. 2 products have an official DRAP price on MedInfoBase. See all 1 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical and veterinary manufacturer
- Address
- Plot 84/1, Block B, Phase V, Industrial Estate, Hattar, Pakistan
- Website
- athanpharmaceuticals.com ↗
- Phone
- +92 995 617520-1; +92 300 3008368
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Athan Pharmaceuticals is priced against the market
2 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Athancef Injection 1gRegistry verified | Cefepime Hydrochloride Monohydra Eq. to Cefepime(with L-Arginine) | — | — | — | 126741Official source ↗ | No indexed price | — | — |
| Athancef Injection 500mgRegistry verified | Cefepime Hydrochloride Monohydra Eq. to Cefepime(with L-Arginine) | — | — | — | 126740Official source ↗ | No indexed price | — | — |
| Hyxopex Injection 1gm IVRegistry verified | Meropenem trihydrate eq to meropenem (Blended with Sodium Carbonate) | — | — | — | 114718Official source ↗ | No indexed price | — | — |
| Hyxopex Injection 500mg IVRegistry verified | Meropenem Trihydarte Eq. to Meropenem | — | — | — | 114717Official source ↗ | No indexed price | — | — |
| Komplet | Colistimethate sodium | 4.5 MIU | Injection | 1's | 137120 | PKR 3,887.00 | PKR 3,887.00/vial/unit | 🔒 Pharma Pro |
| Komplet | Colistimethate sodium | 2 MIU | Injection | 1's | 137121 | PKR 1,727.00 | PKR 1,727.00/vial/unit | 🔒 Pharma Pro |
| Moxelief 1g Injection IMRegistry verified | Ceftriaxone Injection | — | — | — | 129075Official source ↗ | No indexed price | — | — |
| Moxelief 250 mg Injection IMRegistry verified | Ceftriaxone Injection | — | — | — | 129073Official source ↗ | No indexed price | — | — |
| Moxelief 500 mg Injection IMRegistry verified | Ceftriaxone Injection | — | — | — | 129074Official source ↗ | No indexed price | — | — |
| Oleo Capsule 20mgRegistry verified | Omeprazole enteric coated pellets eq to Omeprazole | — | — | — | 108939Official source ↗ | No indexed price | — | — |
| Oleo Capsule 40mgRegistry verified | Omeprazole enteric coated pellets eq to Omeprazole | — | — | — | 101245Official source ↗ | No indexed price | — | — |
| Oleo Injection 40mgRegistry verified | Omeprazole (as Sodium) | — | — | — | 105320Official source ↗ | No indexed price | — | — |
| Ollattyx Eye Drop Solution 2mg/mlRegistry verified | Olopatadine Hydrochloride eq to Olopatadine | — | — | — | 107816Official source ↗ | No indexed price | — | — |
| Oxriax 1g Injection IVRegistry verified | Ceftriaxone Injection | — | — | — | 129283Official source ↗ | No indexed price | — | — |
| Oxriax 250mg Injection IVRegistry verified | Ceftriaxone Injection | — | — | — | 129285Official source ↗ | No indexed price | — | — |
| Oxriax 500mg Injection IVRegistry verified | Ceftriaxone Injection | — | — | — | 129284Official source ↗ | No indexed price | — | — |
| Ozattlic Capsule 20mgRegistry verified | Esomeprazole magnesium trihydrate pellets eq to esomeprazole | — | — | — | 108919Official source ↗ | No indexed price | — | — |
| Ozattlic Capsule 40mgRegistry verified | Esomeprazole magnesium trihydrate pellets eq to esomeprazole | — | — | — | 108918Official source ↗ | No indexed price | — | — |
| Ozattlic Injection 40mgRegistry verified | Esomeprazole as sodium | — | — | — | 108658Official source ↗ | No indexed price | — | — |
| Rectace Injection 1gRegistry verified | Cefoperazone as Sodium, Sulbactam as Sodium | — | — | — | 129489Official source ↗ | No indexed price | — | — |
| Rectace Injection 2gRegistry verified | Cefoperazone as Sodium, Sulbactam as Sodium | — | — | — | 134836Official source ↗ | No indexed price | — | — |
All 1 Athan Pharmaceuticals brands in Pakistan
- Komplet Colistimethate sodium · 2 MIU injection, 4.5 MIU injection
Athan Pharmaceuticals: common questions
How many products does Athan Pharmaceuticals have in Pakistan?
Athan Pharmaceuticals has 2 registered medicine presentations in Pakistan, sold under 1 brand and covering 1 generic medicine.
Which therapy areas does Athan Pharmaceuticals cover?
The most products are in Anti-infectives (2).
Where can I see Athan Pharmaceuticals medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.